Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protagonist Therapeutics

54.38
+0.56001.04%
Post-market: 54.00-0.3800-0.70%19:38 EDT
Volume:1.07M
Turnover:58.16M
Market Cap:3.37B
PE:63.05
High:54.97
Open:54.27
Low:53.10
Close:53.82
Loading ...

Protagonist Therapeutics’ Rusfertide: Promising Efficacy and Financial Upside Drive Buy Recommendation

TIPRANKS
·
03 Jun

Protagonist Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Jun

J.P. Morgan Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)

TIPRANKS
·
03 Jun

Protagonist Therapeutics: Promising Future with Rusfertide as a Standard of Care for Polycythemia Vera

TIPRANKS
·
03 Jun

Protagonist, Takeda announces Phase 3 VERIFY study met primary endpoint

TIPRANKS
·
02 Jun

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

Business Wire
·
01 Jun

Protagonist Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
19 May

Protagonist Therapeutics: Strategic Partnerships and Innovative Therapies Drive Buy Rating

TIPRANKS
·
19 May

Johnson & Johnson, Protagonist Therapeutics Say Psoriasis Drug Cleared Skin in Late-Stage Study

MT Newswires Live
·
09 May

Protagonist announces icotrokinra data from Phase 3 ICONIC-TOTAL study

TIPRANKS
·
09 May

Protagonist Therapeutics: Buy Rating Backed by Promising Clinical Trials and Market Opportunities

TIPRANKS
·
07 May

Protagonist Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
07 May

Protagonist Therapeutics reports Q1 EPS (19c), consensus 11c

TIPRANKS
·
07 May

Protagonist Therapeutics Q1 EPS $(0.19) Misses $0.18 Estimate, Sales $28.32M Miss $30.44M Estimate

Benzinga
·
07 May

Protagonist Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview

Reuters
·
06 May

Protagonist Therapeutics Reports Granting of Inducement Award

ACCESS Newswire
·
17 Apr

Protagonist Therapeutics’ Icotrokinra: A Promising Buy Rating Backed by Strong Efficacy, Safety, and Financial Prospects

TIPRANKS
·
11 Apr

Protagonist Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Apr

Protagonist Therapeutics: Promising Clinical Data and Strategic Expansion Drive Buy Rating

TIPRANKS
·
11 Apr

Promising Potential of Protagonist Therapeutics’ Icotrokinra in Psoriasis Treatment: A Buy Recommendation by Roger Song

TIPRANKS
·
10 Apr